If You Invested $1000 in Veracyte a Decade Ago, This is How Much It'd Be Worth Now

For most investors, how much a stock's price changes over time is important. Not only can it impact your investment portfolio, but it can also help you compare investment results across sectors and industries.The fear of missing out, or FOMO, also plays a factor in investing, especially with particular tech giants, as well as popular consumer-facing stocks.What if you'd invested in Veracyte (VCYT) ten years ago? It may not have been easy to hold on to VCYT for all that time, but if you did, how much would your investment be worth today?Veracyte's Business In-DepthWith that in mind, let's take a look at Veracyte's main business drivers.Headquartered in San Francisco, CA, Veracyte is a global diagnostics company that provides clinicians valuable insights to diagnose and treat cancer. The company has a wide array of advanced genomic tests that leverage deep scientific, clinical and machine learning expertise and other capabilities. Presently, the portfolio includes Afirma (for thyroid cancer), Decipher Prostate (prostate cancer), Prosigna (breast cancer), Envisia (interstitial lung diseases) and Decipher Bladder (bladder cancer), with additional tests in development.These high-performing tests improve diagnostic, prognostic and treatment decisions in cancer and other challenging diseases, helping patients avoid unnecessary procedures and reduce time in finding appropriate treatment.  In the United States, Veracyte offers tests through its central laboratories and makes the tests accessible to patients worldwide by collaborating with local labs. The company recognizes revenues from three sources:Testing revenues (94% of total revenues in 2024, up 28% from 2023): Upon delivery of the test results, the company bills for testing services considering factors such as payer reimbursement history, contracts and coverage.Product revenues (3% of 2024 revenues; down 12%):  Includes revenues from Prosigna breast cancer assay, the nCounter Analysis System (acquired from Nanostring Technologies, Inc. in 2019) and related diagnostic kits.Biopharmaceutical and other revenues (3% of 2024 revenues; down 30%): Includes revenues from licensing or providing access to the company’s assets and services, including testing and contract manufacturing.The company’s 2021 acquisition of Decipher Biosciences expanded its genomic testing menu into urologic cancers and provided Decipher GRID (Genomic Resource for Intelligent Discovery) — a platform and database that helps drive biopharmaceutical partnerships, key opinion leaders (KOL) engagement and pipeline development in urologic cancers.In the same year, Veracyte acquired HalioDx, which enabled it to produce its own in vitro diagnostic (IVD) test kits for use on the nCounter Analysis System. Veracyte intends to migrate the manufacture of the test kits for the nCounter from NanoString to HalioDx. Bottom LineAnyone can invest, but building a successful investment portfolio takes a combination of a few things: research, patience, and a little bit of risk. So, if you had invested in Veracyte a decade ago, you're probably feeling pretty good about your investment today.A $1000 investment made in October 2015 would be worth $6,174.96, or a gain of 517.50%, as of October 6, 2025, according to our calculations. This return excludes dividends but includes price appreciation.The S&P 500 rose 244.16% and the price of gold increased 225.54% over the same time frame in comparison.Analysts are anticipating more upside for VCYT.Veracyte continues the strong growth momentum in its testing business from the sale of Decipher Prostate and Afirma tests. Afirma's volume growth reflects both new accounts and deeper penetration of existing accounts, signaling continued market share gains. The research use-only Afirma GRID offering is also gaining traction. As a key milestone, Veracyte is on track to exceed 100,000 Decipher tests annually for the first time, driven by robust 2025 second-quarter volumes. Progress in terms of all three of its long-term growth drivers is also encouraging. Solid financial health further enhances the stock's appeal. Meanwhile, the sale of Veracyte SAS manufacturing business creates a temporary revenue headwind. The adverse impacts of macroeconomic challenges and an intense competitive landscape may pose operational risks.The stock has jumped 11.01% over the past four weeks. Additionally, no earnings estimate has gone lower in the past two months, compared to 4 higher, for fiscal 2025; the consensus estimate has moved up as well.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Veracyte, Inc. (VCYT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks